Ketanest-S ( DrugBank: - )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
4原発性側索硬化症1
70広範脊柱管狭窄症2

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000142-18-FI
(EUCTR)
09/05/201808/05/2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Amyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Trade Name: Ketanest-S
INN or Proposed INN: ESKETAMINE
Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 4Finland

4. 原発性側索硬化症


臨床試験数 : 7 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000142-18-FI
(EUCTR)
09/05/201808/05/2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Amyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Trade Name: Ketanest-S
INN or Proposed INN: ESKETAMINE
Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 4Finland

70. 広範脊柱管狭窄症


臨床試験数 : 96 薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002887-14-FI
(EUCTR)
31/10/201614/10/2016Dose-response of ketamine in patient controlled analgesia in orthopaedic surgery patientsDose response study of Patient Controlled Analgesia (PCA) of S-ketamine in orthopaedic spine surgery patients - DoseRespKeta Patients who are scheduled for elective posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation
MedDRA version: 19.0;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Trade Name: Ketanest-S
INN or Proposed INN: KETAMINE
Trade Name: Oxycodone Orion
INN or Proposed INN: OXYCODONE
University of TurkuNULLNot RecruitingFemale: yes
Male: yes
100Phase 1;Phase 4Finland
2EUCTR2012-000747-26-FI
(EUCTR)
27/04/201202/04/2012Ketamine to reduce postoperative pain in back surgeryAdministration of S-Ketamine during spinal surgery to reduce postoperative pain adult patients undergoing spinal surgery
MedDRA version: 14.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Trade Name: Ketanest-S
Product Name: Ketanest-S
Other descriptive name: ESKETAMINE HYDROCHLORIDE
Helsinki Universiy Central HospitalNULLNot Recruiting Female: yes
Male: yes
192 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesFinland